Las Vegas, NV -- (SBWIRE) -- 12/06/2012 -- Beststocksdaily is one of leading U.S. stock update providers to valued investors. Following are the notable volume movers as reported by http://beststocksdaily.com/
North American Palladium Ltd (USA) (NYSE:PAL) is currently trading at $1.39, 0.36% lower. North American Palladium Ltd. (NAP) is a precious metals producer that has been operating its flagship Lac des Iles mine (LDI) located in Ontario, Canada. NAP also operates the Vezza gold mine located in the Abitibi region of Quebec.
Can PAL Jump Again? Find Out Here http://beststocksdaily.com/p2/index.php?company=PAL
Brigus Gold Corp (USA) (NYSE:BRD) fell 3.01% to $0.970. Brigus Gold Corp. (Brigus) is a mining company. The Company is engaged in the extraction, processing, and refining of gold deposits, as well as related activities, including the acquisition, exploration and development of mineral properties principally located in North America.
Get Free Trend Analysis on BRD Here http://beststocksdaily.com/p2/index.php?company=BRD
Hemispherx BioPharma, Inc (NYSE:HEB) is lower 1.67% to $0.793. Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.
To Get complete technical analysis on HEB go to http://beststocksdaily.com/p2/index.php?company=HEB
YM BioSciences Inc. (USA) (NYSE:YMI) among the losers and the stock fell 0.62% to $1.60. YM BioSciences Inc. (YM), is a drug development company. The Company is advancing three clinical-stage hematology and cancer-related products. Its CYT387, is an oral small molecule oral dual inhibitor of the JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody, and CYT997, a vascular disrupting agent (VDA).
Get Free Trend Analysis on YMI Here http://beststocksdaily.com/p2/index.php?company=YMI
NovaBay Pharmaceuticals, Inc. (NYSE:NBY) is lower 14.39% to $1.19. NovaBay Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on addressing the unmet therapeutic needs of the global anti-infective market. The Company’s Aganocide compounds, led by NVC-422, are patented, synthetic molecules with a spectrum of activity against bacteria, viruses and fungi. The Company is focused in three therapeutic markets, which includes Dermatology, Ophthalmology and Urology.
To Get complete technical analysis on NBY go to http://beststocksdaily.com/p2/index.php?company=NBY
Beststocksdaily’s team is engaged in providing valuable and updated news information on U.S. stocks on a regular basis. Beststocksdaily’s instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. To Get Instant updates in the inbox, readers are advised to sign up for free at Beststocksdaily.com.
The assembled information disseminated by beststocksdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. beststocksdaily.com does expect that investors will buy and sell securities based on information assembled and presented in beststocksdaily.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)